Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $13.00 at UBS Group

Aveanna Healthcare (NASDAQ:AVAH) had its target price hoisted by equities research analysts at UBS Group from $8.00 to $13.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price objective suggests a potential upside of 5.56% from the stock’s current price.

Several other research firms have also weighed in on AVAH. Royal Bank Of Canada upgraded Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, June 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. Truist Financial boosted their price target on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $10.00 to $11.00 in a research report on Friday, May 15th. Finally, Barclays raised their target price on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Aveanna Healthcare currently has an average rating of “Moderate Buy” and an average price target of $11.78.

Aveanna Healthcare Price Performance

Shares of Aveanna Healthcare stock traded up $1.02 during trading on Friday, reaching $12.31. 4,391,567 shares of the stock traded hands, compared to its average volume of 1,666,656. The business has a fifty day simple moving average of $8.86 and a two-hundred day simple moving average of $7.73. Aveanna Healthcare has a 52-week low of $5.93 and a 52-week high of $12.52. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of 10.43, a P/E/G ratio of 0.90 and a beta of 1.90. The company has a debt-to-equity ratio of 5.35, a current ratio of 1.47 and a quick ratio of 1.47.

Aveanna Healthcare (NASDAQ:AVAH) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.03. Aveanna Healthcare had a return on equity of 124.68% and a net margin of 10.37%.The business had revenue of $670.48 million during the quarter, compared to analysts’ expectations of $638.61 million. Sell-side analysts expect that Aveanna Healthcare will post 0.68 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder J.H. Whitney Equity Partners V sold 5,842,240 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $6.24, for a total value of $36,455,577.60. Following the completion of the transaction, the insider owned 13,450,547 shares of the company’s stock, valued at $83,931,413.28. The trade was a 30.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Robert M. Williams, Jr. sold 7,000,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $6.24, for a total value of $43,680,000.00. Following the completion of the transaction, the insider directly owned 252,899 shares of the company’s stock, valued at $1,578,089.76. The trade was a 96.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 31,305,664 shares of company stock worth $215,555,910. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Aveanna Healthcare

Several institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its position in shares of Aveanna Healthcare by 21.2% in the first quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after acquiring an additional 4,602 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Aveanna Healthcare by 8.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after buying an additional 25,974 shares during the last quarter. Jane Street Group LLC raised its position in Aveanna Healthcare by 522.0% in the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after purchasing an additional 63,010 shares during the period. Creative Planning lifted its position in Aveanna Healthcare by 15.1% in the second quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after buying an additional 6,171 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Aveanna Healthcare by 65.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock worth $828,000 after acquiring an additional 62,348 shares during the last quarter. Institutional investors and hedge funds own 87.96% of the company’s stock.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Strong Q2 beat: Aveanna reported revenue of $670.5 million, up 13.7% year over year, and adjusted earnings of $0.22 per share, exceeding analyst expectations. Net income rose to $40.3 million from $27.0 million, while adjusted EBITDA increased 8% to $95.4 million. Aveanna Healthcare second-quarter results and revised guidance
• Positive Sentiment: Guidance raised: Management now expects 2026 revenue above $2.68 billion, compared with its previous range of $2.63 billion to $2.65 billion. Full-year adjusted EBITDA guidance was increased to more than $365 million from $338 million to $342 million. AVAH Q2 earnings call highlights
• Positive Sentiment: Improved growth outlook: On its earnings call, Aveanna highlighted reimbursement gains, expanding relationships with preferred payers and higher long-term growth targets, supporting expectations for continued demand across its home-care platform.
• Positive Sentiment: Analyst endorsement: BMO Capital Markets raised its AVAH price target from $10 to $14 and upgraded or maintained an “outperform” rating, reinforcing the market’s favorable response to the earnings report.
• Neutral Sentiment: Valuation and momentum: The stock is trading near its 12-month high after gaining substantially since March. Although its forward valuation remains attractive relative to some healthcare peers, the recent rally may increase sensitivity to future results.
• Negative Sentiment: Margin pressure remains a risk: Gross margins declined across Aveanna’s business segments, including Private Duty Services, which generates most of the company’s revenue. Continued revenue growth is currently offsetting that pressure, but weaker margins could limit future earnings expansion.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.